Key Laboratory of Design and Assembly of Functional Nanostructures, Fujian Institute of Research on the Structure of Matter, Chinese Academy of Sciences, Fuzhou 350002, P. R. China.
The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou 350025, P. R. China.
Theranostics. 2019 Jan 1;9(2):369-380. doi: 10.7150/thno.29817. eCollection 2019.
The therapeutic efficacy of fluorescence image-guided tumor surgery and photodynamic therapy (PDT) is impaired by the penetration depth limitation, low signal-to-noise ratio of traditional first near-infrared window (NIR I) fluorescence and the hypoxic tumor microenvironment. Here, a "red blood cell-based multimodal probe" was proposed to achieve enhanced tumor targeting and retention of fluorescent probes after an intravenous injection, so that second near-infrared window (NIR II) fluorescence bioimaging-guided complete tumor resection and high-efficiency photodynamic therapy could then be realized. The hexanoic acid ester-modified rose bengal (RB-HA), RGD (Arginine-Glycine-Aspartic) peptide and avidin were covalently coupled onto amine-modified upconversion nanoparticles (UCNPs) EDC/NHS reaction (UCNPs@RB@RGD@avidin). Afterwards, the complex of ICG with bovine serum albumin (BSA) was loaded into RBCs through hypotonic dialysis (RBC@ICG). Then, the membrane proteins of RBC@ICG were biotinylated by biotin-modified phospholipids (RBC@ICG@biotin). Finally, the RBCp (Red Blood Cell based probe) was obtained by crosslinking UCNPs@RB@RGD@avidin to RBC@ICG@biotin through the interaction of avidin and biotin. The obtained multimodal RBCp was extensively characterized, both and , including analysis of chemical, physical and fluorescent features, O delivery ability, tumor accumulation, NIR II fluorescence bioimaging ability, photodynamic therapeutic efficiency, and biosafety. The RBCp experienced efficient tumor targeting and long tumor retention for almost 4 h after intravenous injection, and the superior signal-to-noise ratio at the optimal time window can be used for guiding precise tumor resection under an 808-nm laser irradiation to facilitate lymph popliteal metastasis surgical delineation. Meanwhile, the RBCp can provide laser-responsive O release to enhance the PDT efficiency of popliteal lymph node metastasis under NIR II fluorescence bioimaging guidance. These excellent performances obviously lead to remarkably enhanced synergistic therapeutic effects of tumor surgery and metastatic inhibition. The proposed strategy will develop a new platform to increase surgical resection completeness and improve PDT efficiency, resulting in the successful and complete inhibition of tumor and metastasis, which could offer a promising approach for the clinical translation of malignant tumor treatment.
荧光引导肿瘤手术和光动力疗法(PDT)的治疗效果受到传统近红外一区(NIR I)荧光穿透深度限制、信噪比低以及缺氧肿瘤微环境的影响。在这里,提出了一种“基于红细胞的多模态探针”,以实现静脉注射后荧光探针的增强肿瘤靶向和保留,从而实现近红外二区(NIR II)荧光生物成像引导的完全肿瘤切除和高效光动力治疗。己酸酯修饰孟加拉玫瑰红(RB-HA)、RGD(精氨酸-甘氨酸-天冬氨酸)肽和亲和素通过 EDC/NHS 反应(UCNPs@RB@RGD@avidin)共价偶联到胺修饰上转换纳米粒子(UCNPs)上。之后,通过低渗透析将吲哚菁绿(ICG)与牛血清白蛋白(BSA)的复合物装入红细胞(RBC@ICG)中。然后,通过生物素修饰的磷脂将 RBC@ICG 的膜蛋白生物素化(RBC@ICG@biotin)。最后,通过 avidin 和 biotin 的相互作用将 UCNPs@RB@RGD@avidin 交联到 RBC@ICG@biotin 上,得到 RBCp(基于红细胞的探针)。对所得多模态 RBCp 进行了广泛的表征,包括化学、物理和荧光特性、O 输送能力、肿瘤积累、NIR II 荧光生物成像能力、光动力治疗效率和生物安全性的分析。静脉注射后,RBCp 经历了有效的肿瘤靶向和长达近 4 小时的肿瘤保留,在最佳时间窗口具有优异的信噪比,可用于在 808nm 激光照射下引导精确肿瘤切除,有助于腘窝淋巴结转移手术描绘。同时,RBCp 可以提供激光响应性 O 释放,以增强 NIR II 荧光生物成像引导下腘窝淋巴结转移的 PDT 效率。这些优异的性能明显导致肿瘤手术和转移抑制的协同治疗效果显著增强。所提出的策略将开发一个新的平台,以提高手术切除的完整性并提高 PDT 效率,从而成功和完全抑制肿瘤和转移,为恶性肿瘤治疗的临床转化提供了一种有前途的方法。